Previous 10 | Next 10 |
HASBROUCK HEIGHTS, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutate (FT), Nymox's first in class lead product for the treatment of benign prostatic hyperpl...
Nymox Pharmaceutical ( NYMX -10.6% ) announces direct offering of $9M shares of its common stock priced at $2.50/share; proceeds will be used for general corporate purposes. More news on: Nymox Pharmaceutical Corporation, Healthcare stocks news, , Stocks on the move, Read mo...
HASBROUCK HEIGHTS, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of shares of its common stock at a purchase price of $2....
HASBROUCK HEIGHTS, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report current updates on the Company's most important ongoing developments. The Company reports further significant and important progress has been made with remaining i...
Thinly traded micro cap Nymox Pharmaceutical Corp. ( NYMX +8.3% ) perks up on almost double normal volume, albeit on turnover of only 264K shares, on the heels of its announcement that its lead fexapotide program in benign prostatic hyperplasia (enlarged prostate) is on track despite COV...
HASBROUCK HEIGHTS, N.J., June 19, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is very pleased to report that key steps in its regulatory submission preparations have been completed and the project is firmly on-track. The majority of its regulatory documentation ...
HASBROUCK HEIGHTS, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the recent allowances of 4 new different US and international patents concerning the Company's prostate enlargement and prostate cancer treatments. The new US a...
HASBROUCK HEIGHTS, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that a new peer review report was published today in the World Journal of Urology, documenting the successful long-term clinical trial results after Fexapotide T...
Nymox Corp (NASDAQ: NYMX ) has been developing NX-1207 for the treatment of benign prostatic hyperplasia (BPH) for the last 20 years. In 2014, two pivotal Phase III trials missed their primary endpoint. Instead of conducting another set of trials in consultation with the FDA and EMA, Nymo...
This article was highlighted for PRO+ subscribers, Seeking Alpha’s service for professional investors. Find out how you can get the best content on Seeking Alpha here . Nymox Pharmaceutical Corp ( NYMX ) is the longest running failure that we have ever seen. The company started i...
News, Short Squeeze, Breakout and More Instantly...
Nymox Pharmaceutical Corporation Company Name:
NYMX Stock Symbol:
NASDAQ Market:
Nymox Pharmaceutical Corporation Website:
IRVINE, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq,...
IRVINE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to provide a mid-2nd quarter update on ongoing activities. The Company reported last month that it expects to submit an additional new submission for marketing...
IRVINE, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to provide a current update on the Company's ongoing projects. The Company recently submitted its application for Marketing Authorization Application to the ...